{"id":392726,"date":"2020-12-03T09:03:31","date_gmt":"2020-12-03T14:03:31","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=392726"},"modified":"2020-12-03T09:03:31","modified_gmt":"2020-12-03T14:03:31","slug":"axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\/","title":{"rendered":"AXIM\u00ae Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company\u2019s Fourth COVID-19 Test-Focused Patent Application"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, Dec.  03, 2020  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kwhTgmj6R61r8NQTauvlCe_GKQwWfDEmegjUhPTy22SJxt-2OukFDPlOYTaHkFjMFRQhf0_pmOBFzIFrzY-ZKnS9ejd_sNNdXcZmqWVOUMuG6p_f8O2LS0WedDpZXj1I6eTU1oxrfcSSwijaSLlnd9DfRuFV9FUiFRzHjY46KJlZY9hkDIi1-DC42zOIQvULXNxZjJeDXNPa6IfN9KwGZP-4X7C8dxfL0M7EhQUyaUb6vpWHxAKa6FZwXYB4uOI9VRtl4REDT2YwkOvq5OpDYw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>AXIM\u00ae Biotechnologies, Inc.<\/u><\/strong><\/a>\u00a0(OTCQB: AXIM) (\u201cAXIM\u00ae Biotech,\u201d \u201cAXIM\u201d or the \u201cCompany\u201d), an international healthcare solutions company targeting oncological and COVID-19 research, announced today the development and patent filing for an enzyme-linked immunosorbent assay (ELISA)-based diagnostic test (the \u201cTest\u201d) for the detection of SARS\u2010CoV-2 neutralizing antibodies. This application marks AXIM\u2019s fourth COVID-19 neutralizing antibody-focused patent application. The Company heavily focuses its resources on advancing research on what it believes will soon become the most prevalent need in the post-vaccine COVID-19 fight, the need to know levels of neutralizing antibodies in longitudinal studies of vaccine response.<\/p>\n<p align=\"left\">\u201cFrom the onset of the pandemic, our scientists have dedicated themselves to creating solutions focused on neutralizing antibody detection. Since no one knows how long vaccines will provide immunity, we continue our development of neutralizing antibody COVID-19 tests,\u201d said AXIM\u00ae Biotech CEO John W. Huemoeller II. \u201cWith the addition of our ELISA-based neutralizing antibody diagnostic test, AXIM hopes to help simplify the testing process for determining a vaccine\u2019s efficacy through clinics across the world.\u201d<\/p>\n<p align=\"left\">AXIM has internally developed the Test, and its own reagents and proteins used in the test kits. The Company has just completed live SARS-CoV-2 virus microneutralization tests at a Biosafety Level (BSL-3) laboratory\u00a0with samples from COVID-19 patients to validate diagnostic tests per current Food and Drug Administration (FDA) guidelines. AXIM intends to file its third Emergency Use Authorization (EUA) with the FDA soon.<\/p>\n<p align=\"left\">The Company\u2019s additional pending COVID-19 testing-focused patents include:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:left\">\n          <a href=\"https:\/\/www.globenewswire.com\/news-release\/2020\/07\/23\/2066638\/0\/en\/AXIM-Biotechnologies-Releases-Rapid-NeuCovix-Test-Results-Showing-Strong-Agreement-with-COVID-19-Based-Neutralization-Tests.html\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n            <u>Rapid point-of-care neutralizing antibody test that delivers results in 10 minutes <\/u><br \/>\n          <\/a>\n        <\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"text-align:left\">\n          <a href=\"https:\/\/www.globenewswire.com\/news-release\/2020\/08\/05\/2073337\/0\/en\/AXIM-Biotechnologies-Applies-for-FDA-Emergency-Use-Approval-EUA-for-High-Throughput-Patent-Pending-Neutralizing-Antibody-Diagnostic-Test-for-COVID-19.html\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n            <u>NeuCovix-HT\u2122<\/u><br \/>\n          <\/a><br \/>\n          <a href=\"https:\/\/www.globenewswire.com\/news-release\/2020\/08\/05\/2073337\/0\/en\/AXIM-Biotechnologies-Applies-for-FDA-Emergency-Use-Approval-EUA-for-High-Throughput-Patent-Pending-Neutralizing-Antibody-Diagnostic-Test-for-COVID-19.html\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n            <u>, a high throughput (HT) diagnostic test that measures levels of functional neutralizing antibodies in plasma or serum<\/u><br \/>\n          <\/a>\u00a0<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt;text-align:left\">\n          <a href=\"https:\/\/www.globenewswire.com\/news-release\/2020\/09\/30\/2101432\/0\/en\/AXIM-Biotechnologies-Files-Patent-for-Virus-Binding-Recombinant-Protein-for-SARS-CoV-2-COVID-19-and-Begins-Manufacturing.html\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n            <u>Recombinant virus binding protein (VBP) for SARS-CoV-2<\/u><br \/>\n          <\/a> that is more potent and stable than current VBP options on the market<\/li>\n<\/ul>\n<p>The ELISA test is\u00a0the most widely used type of immunoassay in diagnostic and research labs.\u00a0ELISA is a high throughput test used to detect or quantify various biomolecules, including antibodies against pathogens or pathogen-derived proteins. ELISA is simple, sensitive, requires only microliter quantities of test samples and can be automated.<\/p>\n<p>\u201cUnlike few currently available ELISA, our uniquely designed assay offers a simple and relatively short test time to detect and rank SARS-CoV-2 neutralizing antibodies by their potency. We believe it will help to evaluate the immune status of patients who recovered from COVID-19 or to monitor immunization efficiency more accurately than other ELISAs,\u201d said AXIM\u00ae Biotech Chief Technology Officer Alim Seit-Nebi, Ph.D.<\/p>\n<p align=\"left\">To learn more about AXIM\u2019s COVID-19 focused research, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=093ZeuJEiVaNMUq6GaUjpzezEiZxAHDwL1QrvJFUgYBW76nv4P0cFLY_I_4hP3rSnomFKlRUyDlnvj-vfsJj8llRuzOyHkMwxncH3mDpMSpoVrHft8UWRYwK99F5eSC1yY8VUzxO2BJAiUvbT8VnfJm5-8Se0A8QW_ifTQPM2y1V5fCO-Wb5NS5xP2Sb7RYM\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>https:\/\/aximbiotech.com\/science\/covid-19-diagnostic-research\/<\/u><\/a>.<\/p>\n<p align=\"left\">\n        <strong>About AXIM\u00ae Biotechnologies<\/strong><br \/>\n        <br \/>Founded in 2014, AXIM\u00ae Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). AXIM\u2019s COVID-19 rapid neutralizing antibody test is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2rmKXyg_Cn3gXyJkMvBt9NYmY4y3780NvnjQ2ptoMqK_6BzmyMwYHWm4qUqtYXnCtq2q9m3XkM5yEk1aCxqJEulaCssVNaQnxBoRpu_EaQQ=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.AXIMBiotech.com<\/u><\/a>.<\/p>\n<p align=\"left\">\n        <strong><br \/>\n          <em>FORWARD-LOOKING DISCLAIMER<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>The statements made by Axim Biotechnologies Inc., in this press release may be \u201cforward-looking\u201d in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim\u2019s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to there being no assurance that our diagnostic candidate will be successfully shown to detect SARS-CoV-2 neutralizing antibodies, that the diagnostic candidate will be approved for use by the U.S. FDA or any equivalent foreign regulatory agency, that the diagnostic candidate can be manufactured in large quantities or that third parties with an established presence in blood collection clinics, vaccine development, employer or individual use will enter into agreements or purchase from the Company, and even if the Company\u2019s diagnostic candidate is successful, it may generate only limited revenue and profits for the Company, including whether any of Axim\u2019s diagnostic products will receive\u00a0clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to sell its products and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, the fact that there has never been a commercial diagnostic test utilizing neutralizing antibodies approved for use and various other factors detailed from time to time in Axim\u2019s SEC reports and filings, including our Annual Report on Form 10-K filed on May 13, 2020 and our subsequent quarterly report on Form 10-Q filed on June 30, 2020, and other reports we file with the SEC, which are available at\u00a0<u>www.sec.gov<\/u>. Axim Biotechnologies, Inc., undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.<\/p>\n<p align=\"left\">\n        <strong>CONTACT:<\/strong><br \/>\n        <br \/>\n        <strong>Public Relations Contact:<\/strong><br \/>\n        <br \/>Kathryn Brown<br \/>Account Supervisor<br \/>CMW Media<br \/>P. 858-264-6600<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YPMXnJ9A74--SZmlc96v-FjKA5qG5chkOiRpkJ68GN72p0W_eCm_W0AtoxK5Z-_VHto0tlY0FO7BmYXOvahiG27NaI0d9TxnoI2CTUda0p0=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>kathryn@cmwmedia.com<\/u><\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=alPcMNvHI8ZwcDaDDau-vev7i8-QbIn63tVQq-viJcl-ewMgiLqu5wGEchLoxqOkFM4dqshcm1Yho6iz19uB3Q==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.cmwmedia.com<\/u><\/a><\/p>\n<p align=\"left\">\n        <strong>AXIM Corporate Contact Info:<\/strong><br \/>\n        <br \/>6191 Cornerstone Ct., Ste. 114<br \/>San Diego, CA 92121, USA<br \/>P. 858-923-4422<\/p>\n<p align=\"left\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>\n        <strong><br \/>\n          <u><br \/>\n            <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WK0h_AffpBYp6ZMznNd8Iw47dRkJ2vjPPjYV_dsNoT7LIsl2vM4SG7IYMMuP4vtDdyvB3V_7BB1_WGQQu18ZIBCf5SFVANuX4M1mvlg6op4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">investors@aximbiotech.com<\/a><br \/>\n          <\/u><br \/>\n        <\/strong><br \/>\n        <br \/>888-759-0844<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjA1MyMzODU0Mjk1IzIwMjM5OTE=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/7586fc7a-5339-4341-9dc2-88f953e10758\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Dec. 03, 2020 (GLOBE NEWSWIRE) &#8212; AXIM\u00ae Biotechnologies, Inc.\u00a0(OTCQB: AXIM) (\u201cAXIM\u00ae Biotech,\u201d \u201cAXIM\u201d or the \u201cCompany\u201d), an international healthcare solutions company targeting oncological and COVID-19 research, announced today the development and patent filing for an enzyme-linked immunosorbent assay (ELISA)-based diagnostic test (the \u201cTest\u201d) for the detection of SARS\u2010CoV-2 neutralizing antibodies. This application marks AXIM\u2019s fourth COVID-19 neutralizing antibody-focused patent application. The Company heavily focuses its resources on advancing research on what it believes will soon become the most prevalent need in the post-vaccine COVID-19 fight, the need to know levels of neutralizing antibodies in longitudinal studies of vaccine response. \u201cFrom the onset of the pandemic, our scientists have dedicated themselves to creating solutions focused on neutralizing antibody detection. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AXIM\u00ae Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company\u2019s Fourth COVID-19 Test-Focused Patent Application&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-392726","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AXIM\u00ae Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company\u2019s Fourth COVID-19 Test-Focused Patent Application - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AXIM\u00ae Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company\u2019s Fourth COVID-19 Test-Focused Patent Application - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Dec. 03, 2020 (GLOBE NEWSWIRE) &#8212; AXIM\u00ae Biotechnologies, Inc.\u00a0(OTCQB: AXIM) (\u201cAXIM\u00ae Biotech,\u201d \u201cAXIM\u201d or the \u201cCompany\u201d), an international healthcare solutions company targeting oncological and COVID-19 research, announced today the development and patent filing for an enzyme-linked immunosorbent assay (ELISA)-based diagnostic test (the \u201cTest\u201d) for the detection of SARS\u2010CoV-2 neutralizing antibodies. This application marks AXIM\u2019s fourth COVID-19 neutralizing antibody-focused patent application. The Company heavily focuses its resources on advancing research on what it believes will soon become the most prevalent need in the post-vaccine COVID-19 fight, the need to know levels of neutralizing antibodies in longitudinal studies of vaccine response. \u201cFrom the onset of the pandemic, our scientists have dedicated themselves to creating solutions focused on neutralizing antibody detection. &hellip; Continue reading &quot;AXIM\u00ae Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company\u2019s Fourth COVID-19 Test-Focused Patent Application&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-03T14:03:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjA1MyMzODU0Mjk1IzIwMjM5OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AXIM\u00ae Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company\u2019s Fourth COVID-19 Test-Focused Patent Application\",\"datePublished\":\"2020-12-03T14:03:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\\\/\"},\"wordCount\":918,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NjA1MyMzODU0Mjk1IzIwMjM5OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\\\/\",\"name\":\"AXIM\u00ae Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company\u2019s Fourth COVID-19 Test-Focused Patent Application - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NjA1MyMzODU0Mjk1IzIwMjM5OTE=\",\"datePublished\":\"2020-12-03T14:03:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NjA1MyMzODU0Mjk1IzIwMjM5OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NjA1MyMzODU0Mjk1IzIwMjM5OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AXIM\u00ae Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company\u2019s Fourth COVID-19 Test-Focused Patent Application\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AXIM\u00ae Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company\u2019s Fourth COVID-19 Test-Focused Patent Application - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\/","og_locale":"en_US","og_type":"article","og_title":"AXIM\u00ae Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company\u2019s Fourth COVID-19 Test-Focused Patent Application - Market Newsdesk","og_description":"SAN DIEGO, Dec. 03, 2020 (GLOBE NEWSWIRE) &#8212; AXIM\u00ae Biotechnologies, Inc.\u00a0(OTCQB: AXIM) (\u201cAXIM\u00ae Biotech,\u201d \u201cAXIM\u201d or the \u201cCompany\u201d), an international healthcare solutions company targeting oncological and COVID-19 research, announced today the development and patent filing for an enzyme-linked immunosorbent assay (ELISA)-based diagnostic test (the \u201cTest\u201d) for the detection of SARS\u2010CoV-2 neutralizing antibodies. This application marks AXIM\u2019s fourth COVID-19 neutralizing antibody-focused patent application. The Company heavily focuses its resources on advancing research on what it believes will soon become the most prevalent need in the post-vaccine COVID-19 fight, the need to know levels of neutralizing antibodies in longitudinal studies of vaccine response. \u201cFrom the onset of the pandemic, our scientists have dedicated themselves to creating solutions focused on neutralizing antibody detection. &hellip; Continue reading \"AXIM\u00ae Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company\u2019s Fourth COVID-19 Test-Focused Patent Application\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-03T14:03:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjA1MyMzODU0Mjk1IzIwMjM5OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AXIM\u00ae Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company\u2019s Fourth COVID-19 Test-Focused Patent Application","datePublished":"2020-12-03T14:03:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\/"},"wordCount":918,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjA1MyMzODU0Mjk1IzIwMjM5OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\/","name":"AXIM\u00ae Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company\u2019s Fourth COVID-19 Test-Focused Patent Application - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjA1MyMzODU0Mjk1IzIwMjM5OTE=","datePublished":"2020-12-03T14:03:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjA1MyMzODU0Mjk1IzIwMjM5OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NjA1MyMzODU0Mjk1IzIwMjM5OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AXIM\u00ae Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company\u2019s Fourth COVID-19 Test-Focused Patent Application"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/392726","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=392726"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/392726\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=392726"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=392726"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=392726"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}